(Q54101702)

24 May 2018

title

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. (English)

1 reference

24 May 2018

0 references

1 reference

1 reference

G F Handeland

1

1 reference

24 May 2018

U Abildgaard

series ordinal

2

1 reference

24 May 2018

H A Holm

series ordinal

3

1 reference

24 May 2018

K E Arnesen

series ordinal

4

1 reference

24 May 2018

publication date

1 January 1990

1 reference

24 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

24 May 2018

volume

39

1 reference

24 May 2018

issue

2

1 reference

24 May 2018

page(s)

107-112

1 reference

24 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00280041

exact match

0 references

cites work

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00280041

Heparin therapy adjusted for body weight

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00280041

Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers

1 reference

12 December 2020

The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays.

1 reference

12 December 2020

On the molecular-weight-dependence of the anticoagulant activity of heparin

1 reference

12 December 2020

Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications

1 reference

12 December 2020

[Prevention of thromboembolic complications in orthopedic surgery]

1 reference

12 December 2020

Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously

1 reference

12 December 2020

Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma

1 reference

12 December 2020

Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding.

1 reference

12 December 2020

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation

1 reference

12 December 2020

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

1 reference

12 December 2020

Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients

1 reference

12 December 2020

Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients

1 reference

12 December 2020

An overview of clinical trials of low molecular weight heparin fractions.

1 reference

12 December 2020

Heparin doses and major bleedings

1 reference

12 December 2020

Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage

1 reference

12 December 2020

Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin

1 reference

12 December 2020

Pharmacokinetics of low molecular weight heparins

1 reference

12 December 2020

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

1 reference

12 December 2020

Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy

1 reference

12 December 2020

A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis

1 reference

12 December 2020

Low molecular weight heparin fraction PK 10169: a new therapeutic means for anticoagulant therapy?

1 reference

12 December 2020

Roentgen diagnosis of venous thrombosis in the leg

1 reference

12 December 2020

The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits

1 reference

12 December 2020

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration

1 reference

12 December 2020

Simplified chromogenic substrate assay for low molecular weight heparin

1 reference

12 December 2020

Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration

1 reference

12 December 2020

Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction

1 reference

12 December 2020

Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin

1 reference

12 December 2020

On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure

1 reference

12 December 2020

Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement

1 reference

12 December 2020

The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin

1 reference

12 December 2020

Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

1 reference

12 December 2020

Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00280041

1 reference

24 May 2018

PubMed ID

2174783

1 reference

24 May 2018